BioCentury | May 20, 2019
Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

...active ulcerative colitis. Phase III miss for Ocular's glaucoma therapy Ocular Therapeutix Inc. (NASDAQ:OCUL) said OTX-TP...
...points; the endpoint required significance at all nine. OTX-TP is an intracanalicular insert that delivers sustained-release travoprost...
...1 Brian Moy, Assistant Editor Entyvio, vedolizumab (MLN0002) inclisiran (aln-pcssc, pcsk9si) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Nuplazid, pimavanserin (ACP-103, pimavanserin tartrate) Sustained-release travoprost (OTX-TP) Acadia...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...muscular atrophy (SMA) type 1 FDA action; EC action June; mid-2019 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Type II diabetes Submit MAA and NDA; submit Japanese NDA 1H19 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...women with low fertility Ph III IMPLANT 2 data 1Q18 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost (OTX-TP...
BioCentury | Oct 10, 2016
Clinical News

Sustained-release travoprost: Phase III started

...Sustained-release travoprost ( OTX-TP ) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release travoprost...
BioCentury | Feb 18, 2016
Clinical News

Ocular Therapeutix rises on OTX-TP update

...to $8.67 on Wednesday after it announced plans for two Phase III placebo-controlled trials of OTX-TP...
...III program. In a previous study, timolol outperformed OTX-TP, a hydrogel-based punctum plug that delivers sustained-release travoprost...
...it reported top-line data showing timolol eye drops led to a greater IOP reduction than OTX-TP...
BioCentury | Nov 2, 2015
Clinical News

Sustained-release travoprost: Phase IIb data

...data from a double-blind, U.S. Phase IIb trial in 73 patients showed that 0.36 mg OTX-TP...
...60 by 4.8 mmHg vs. 6.4 mmHg for twice-daily timolol eye drops. At day 90, OTX-TP...
...Sustained-release travoprost ( OTX-TP ) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release travoprost...
BioCentury | Dec 15, 2014
Clinical News

Sustained Release Travoprost: Phase IIb started

...Sustained Release Travoprost (OTX-TP) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release travoprost...
BioCentury | Jul 21, 2014
Emerging Company Profile

Envisia: Ophthalmic nanotechnology

Envisia Therapeutics Inc. is using its PRINT microparticle formulation technology to develop sustained-release, implantable versions of approved drugs for glaucoma and age-related macular edema. The products could solve compliance problems with existing therapeutics and could...
BioCentury | Jan 29, 2013
Financial News

Ocular raises $23.8M in series D extension

...to start around the end of 2014. OTX-TP2 is a hydrogel-based punctum plug that delivers sustained-release travoprost...
Items per page:
1 - 10 of 15